诺诚健华 港股通 空最新回购 (2025-10-10) 官网 ( 09969.hk) | -92.04 | 2.96 | 0% | 上市时间2020-03-23股价12.20港币涨跌幅-0.41%成交金额6,061.61万港币换手率0.28%市值215.29亿港币H股市值182.55亿港币总股本17.65亿H股本14.96亿每手股数1,000上市至今年化投资收益率3.12%港股通持仓占H股比例30.86% (56.93亿港币2026-01-19) 累计做空占H股比例2.55% (5.14亿港币2026-01-09) | |||
| 所属三级行业生物技术 (恒生) | 市盈率 | 68.21 | 市净率 | 5.18 | 股息率 | 0.30% | 恒生:医疗保健业药品及生物科技生物技术 |
| 所属指数指数纳入纳出 | |||||||
| 同股同权 | 查看历史折扣 | ||||||
| 备注 (8): | 双击编辑备注 |
诺诚健华(09969) - 历史董事名单
| # | 姓名 | 职衔 | 职位 | 委任日期 | 辞任日期 |
|---|---|---|---|---|---|
| 1 | 董丹丹 | Independent Non Executive Director | 2023-10-11 | -- | |
| 2 | 金明 | Non Executive Director | 2022-03-31 | -- | |
| 3 | 謝榕剛 | Non Executive Director | 2021-03-31 | -- | |
| 4 | 陳凱先 | Independent Non Executive Director | 2020-03-11 | -- | |
| 5 | 胡蘭 | Independent Non Executive Director - A/F | 2020-03-11 | -- | |
| 6 | CUI Ji Song | Executive Director | Chairman, CEO | 2019-09-27 | -- |
| 7 | ZHAO Renbin | Executive Director | 2019-09-27 | -- | |
| 8 | ZHANG Zemin Jason | Independent Non Executive Director | 2019-09-27 | 2023-07-14 | |
| 9 | 付山 | Non Executive Director | 2019-09-27 | 2023-03-27 | |
| 10 | 苑全紅 | Non Executive Director | 2019-09-27 | 2022-03-31 | |
| 11 | 林利軍 | Non Executive Director | 2019-09-27 | 2021-03-31 | |
| 12 | 施一公 | Non Executive Director | 2015-11-03 | -- |